Market Size, Leading Therapies, and Dominant Players
In 2023, the top-selling CAR-T therapies were Yescarta, with $1.8 billion in sales; Kymriah, with $1.2 billion; and Carvykti, with $0.9 billion. The field is concentrated among a handful of large pharmaceutical companies: Novartis, Gilead, Bristol-Myers Squibb, and Johnson & Johnson. The United States accounts for 65 percent of global CAR-T therapy revenue, reflecting its early lead in approvals and adoption. The first CAR-T treatment received U.S. approval in 2017, offering a new option for patients with certain blood cancers that had stopped responding to standard treatments. While other immunotherapies such as checkpoint inhibitors had helped many patients, a large share still saw their cancers progress, and CAR-T therapy provided an additional tool.
Cost, Coverage, and Manufacturing as Critical Barriers
Despite the promise, the cost of a single infusion remains a significant hurdle. In the United States, the price for one CAR-T therapy infusion ranges from $373,000 to $475,000, and that figure does not include hospitalization and ancillary costs. Medicare covers CAR-T therapy under the Inpatient Prospective Payment System, and as of 2024, 42 states have Medicaid coverage. The expansion of Medicare and Medicaid coverage in recent years has helped improve access, but the therapy remains prohibitively expensive for many patients. Manufacturing is another critical bottleneck. For autologous products, which are custom-made from each patient’s own cells, the vein-to-vein time averages three to four weeks. The development of allogeneic, or off-the-shelf, donor-cell products is one of the key drivers of the projected market growth, according to the Grand View Research report. Expanding manufacturing capacity is another core factor pushing the market forward, as more hospitals and insurers adopt the therapy.
Risks, Origins, and a Cautious Outlook
The rapid growth of the market signals increasing institutional adoption, but the field remains one where hope must be balanced with caution. CAR-T therapy is not a cure for every patient, and it carries serious risks, including cytokine release syndrome and neurological side effects. The market is concentrated in the hands of a few large players, and the logistical complexity of production remains a barrier. For now, patients should talk to their doctor about whether CAR-T therapy is an appropriate option for their specific diagnosis and what the financial implications might be. The therapy’s trajectory will continue to shape how aggressive cancers are treated in the years ahead.
The scientific foundation for CAR-T therapy stems from earlier work with tumor-infiltrating lymphocytes, or TILs. In the late 1980s, researchers at the National Institutes of Health showed that TILs grown from mouse tumors could shrink tumors when transferred back into the animals. That line of investigation led to treatments for metastatic melanoma. Scientists then began engineering T cells directly rather than relying on naturally occurring ones, and CAR-T therapy developed from that research. With a projected market of $18.2 billion by 2030, and with manufacturing innovations and new approvals on the horizon, CAR-T therapy is likely to become an increasingly important tool in the fight against cancer. Yet many patients currently face a long wait for manufacturing, because each dose is custom-made from their own cells, and the emerging generation of off-the-shelf products aims to shorten that delay. The rapid growth of the market means more approved uses, making more patients potentially eligible, but access still depends on insurance coverage and manufacturing capacity. As always, patients should consult their doctor to understand the latest developments and what they might mean for their individual treatment plan.
